Lanitop (Metildigoxin)

Metildigoxin inhibits the Na⁺/K⁺‑ATPase pump in heart muscle cells, leading to increased intracellular calcium. The higher calcium level strengthens heart contractions (positive inotropy) while the drug also slows conduction through the atrioventricular node, providing a negative chronotropic effect.

The dosage of Lanitop is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, renal function, electrolyte status, and response to therapy.

Safety of Metildigoxin in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Lanitop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanitop (Metildigoxin) belongs to the cardiac glycoside class, similar to digoxin. Both agents share the same mechanism of increasing intracellular calcium and slowing AV nodal conduction, but Metildigoxin may differ in potency, pharmacokinetic profile, and specific regulatory status in various regions.

Lanitop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Lanitop is administered orally, typically as a tablet taken with or without food as directed by the prescribing clinician. The exact timing and any dose adjustments are guided by therapeutic drug monitoring and clinical response.

The most serious risks include life‑threatening arrhythmias, severe bradycardia or heart block, and hyperkalemia. Patients should be monitored for signs of cardiac toxicity, visual disturbances, and electrolyte abnormalities.

Lanitop is contraindicated in patients with known hypersensitivity to Metildigoxin or other cardiac glycosides, in those with uncontrolled ventricular arrhythmias, and in individuals with severe electrolyte disturbances such as high potassium levels. Caution is also advised for patients with severe renal impairment.